US11608343 — Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2041-07-21 · 15y remaining
What this patent protects
This patent protects new compounds and their use as inhibitors of the HER2 protein and its mutants in treating and preventing oncological diseases.
USPTO Abstract
The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R 1 , R 2 , R 3 and R 4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
Drugs covered by this patent
- Hernexeos (ZONGERTINIB) · Boehringer Ingelheim
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-4245 |
— | Hernexeos |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.